NCT07050212View on ClinicalTrials.gov

Application of Remimazolam, Dexmedetomidine, and Esketamine in Pediatric Preoperative Sedation

NARecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2026

Conditions
RemimazolamDexmedetomidineEsketamine
Interventions
DRUG

remimazolam group

remimazolam is administered intravenously at a dose of 0.3 mg/kg

DRUG

dexmedetomidine group

dexmedetomidine is administered intravenously at a dose of 1 μg/kg

DRUG

esketamine group

esketamine is administered intravenously at a dose of 0.5 mg/kg

Trial Locations (1)

430000

RECRUITING

Maternal and Child Health Hospital of Hubei Province, Wuhan

All Listed Sponsors
lead

Maternal and Child Health Hospital of Hubei Province

OTHER